Comparison of individual-level and population-level risk factors for rhinoconjunctivitis, asthma, and eczema in the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three.
Asthma
Eczema
Global
Multimorbidity
Rhinoconjunctivitis
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
11
11
2019
revised:
08
04
2020
accepted:
24
04
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema in children cluster at both the individual and population levels. To assess individual-level and school-level risk factors for symptoms of rhinoconjunctivitis and compare them to corresponding associations with symptoms of asthma and eczema in Phase Three of the International Study of Asthma and Allergies in Childhood. We studied 116,863 children aged 6-7 years from 2163 schools in 59 centres and 22 countries and 224,436 adolescents aged 13-14 years from 2037 schools in 97 centres in 41 countries. Multilevel logistic regression models were fitted with random intercepts for school, centre, and country, adjusting for sex and maternal education at the child level. Associations between symptoms and a range of lifestyle and environmental risk factors were assessed for both the child's exposure and mean exposure at the school. Models were fitted for rhinoconjunctivitis, asthma, and eczema singly (unimorbidity) and for combinations of these conditions (multimorbidity). Generally, associations between symptoms and exposures at the school level were similar in direction and magnitude to those at the child level. Associations with multimorbidity were stronger than for unimorbidity, particularly in individuals with symptoms of all three diseases, but risk factor associations found in conventional single disease analyses persisted among children with only one condition, after excluding multimorbid groups.Comparisons of individuals with only one disease showed that many risk factor associations were consistent across the three conditions. More strongly associated with asthma were low birthweight, cat exposure in infancy, and current maternal smoking. Current paracetamol use was more strongly associated with asthma and rhinoconjunctivitis than eczema. Breastfeeding was more strongly associated with eczema than asthma or rhinoconjunctivitis.The direction and magnitude of most risk factor associations were similar in affluent and non-affluent countries, although notable exceptions include farm animal contact in infancy and larger sibships, which were associated with increased risk of rhinoconjunctivitis in non-affluent countries but reduced risk in affluent countries. In both age groups, current paracetamol use increased risk of each disease to a greater extent in affluent countries than in non-affluent countries. Effects of paracetamol and antibiotics in infancy were more consistent between richer and poorer settings. Most of the environmental and lifestyle correlates of rhinoconjunctivitis, asthma and eczema in childhood display similarity across the three conditions, even in less affluent settings where allergic sensitisation is less likely to explain the concordant epidemiological patterns. Not applicable.
Sections du résumé
BACKGROUND
BACKGROUND
Symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema in children cluster at both the individual and population levels.
OBJECTIVES
OBJECTIVE
To assess individual-level and school-level risk factors for symptoms of rhinoconjunctivitis and compare them to corresponding associations with symptoms of asthma and eczema in Phase Three of the International Study of Asthma and Allergies in Childhood.
METHODS
METHODS
We studied 116,863 children aged 6-7 years from 2163 schools in 59 centres and 22 countries and 224,436 adolescents aged 13-14 years from 2037 schools in 97 centres in 41 countries. Multilevel logistic regression models were fitted with random intercepts for school, centre, and country, adjusting for sex and maternal education at the child level. Associations between symptoms and a range of lifestyle and environmental risk factors were assessed for both the child's exposure and mean exposure at the school. Models were fitted for rhinoconjunctivitis, asthma, and eczema singly (unimorbidity) and for combinations of these conditions (multimorbidity).
RESULTS
RESULTS
Generally, associations between symptoms and exposures at the school level were similar in direction and magnitude to those at the child level. Associations with multimorbidity were stronger than for unimorbidity, particularly in individuals with symptoms of all three diseases, but risk factor associations found in conventional single disease analyses persisted among children with only one condition, after excluding multimorbid groups.Comparisons of individuals with only one disease showed that many risk factor associations were consistent across the three conditions. More strongly associated with asthma were low birthweight, cat exposure in infancy, and current maternal smoking. Current paracetamol use was more strongly associated with asthma and rhinoconjunctivitis than eczema. Breastfeeding was more strongly associated with eczema than asthma or rhinoconjunctivitis.The direction and magnitude of most risk factor associations were similar in affluent and non-affluent countries, although notable exceptions include farm animal contact in infancy and larger sibships, which were associated with increased risk of rhinoconjunctivitis in non-affluent countries but reduced risk in affluent countries. In both age groups, current paracetamol use increased risk of each disease to a greater extent in affluent countries than in non-affluent countries. Effects of paracetamol and antibiotics in infancy were more consistent between richer and poorer settings.
CONCLUSIONS
CONCLUSIONS
Most of the environmental and lifestyle correlates of rhinoconjunctivitis, asthma and eczema in childhood display similarity across the three conditions, even in less affluent settings where allergic sensitisation is less likely to explain the concordant epidemiological patterns.
TRIAL REGISTRATION
BACKGROUND
Not applicable.
Identifiants
pubmed: 32642022
doi: 10.1016/j.waojou.2020.100123
pii: S1939-4551(20)30026-0
pii: 100123
pmc: PMC7334817
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100123Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors report no competing interests.
Références
Allergy. 2018 Jul;73(7):1447-1458
pubmed: 29331026
Lancet. 2008 Sep 20;372(9643):1039-48
pubmed: 18805332
Pediatr Allergy Immunol. 2014 May;25(3):264-70
pubmed: 24750571
Am J Respir Crit Care Med. 2011 Jan 15;183(2):171-8
pubmed: 20709817
Int J Epidemiol. 2014 Dec;43(6):1846-54
pubmed: 25056339
Thorax. 2012 Nov;67(11):941-9
pubmed: 22693180
Int J Tuberc Lung Dis. 2005 Jan;9(1):10-6
pubmed: 15675544
Lancet Respir Med. 2013 Jul;1(5):386-94
pubmed: 24429203
Int J Epidemiol. 2012 Jun;41(3):753-61
pubmed: 22287135
Allergol Immunopathol (Madr). 2011 Nov-Dec;39(6):318-25
pubmed: 21802826
Lancet Respir Med. 2014 Feb;2(2):131-40
pubmed: 24503268
Allergy Asthma Immunol Res. 2015 Jan;7(1):44-50
pubmed: 25553262
Clin Exp Allergy. 2019 Apr;49(4):430-441
pubmed: 30508327
Am J Respir Crit Care Med. 2007 Sep 15;176(6):565-74
pubmed: 17575099
Eur Respir J. 2004 Sep;24(3):406-12
pubmed: 15358699
J Asthma Allergy. 2016 May 11;9:93-100
pubmed: 27257389
Epidemiology. 2012 Sep;23(5):742-50
pubmed: 22828662
Allergy. 2018 Oct;73(10):1964-1978
pubmed: 29869791
J Allergy Clin Immunol. 2019 Mar;143(3):894-913
pubmed: 30639346
J Invest Dermatol. 2019 May;139(5):1023-1036
pubmed: 30521836
Pediatr Allergy Immunol. 2013 May;24(3):293-8
pubmed: 23551831
J Allergy Clin Immunol. 2009 Nov;124(5):982-9
pubmed: 19895986
Clin Exp Allergy. 2015 Jan;45(1):126-36
pubmed: 24912652
Eur Respir J. 1995 Mar;8(3):483-91
pubmed: 7789502
Front Pediatr. 2017 Mar 03;5:44
pubmed: 28316969
PLoS One. 2017 Jun 9;12(6):e0179125
pubmed: 28598986
Allergy. 2019 Apr;74(4):824-827
pubmed: 30474280
J Allergy Clin Immunol. 2017 Feb;139(2):388-399
pubmed: 28183433
J Allergy Clin Immunol. 2019 Jan;143(1):46-55
pubmed: 30458183
Thorax. 2013 Apr;68(4):351-60
pubmed: 23319429
Nat Genet. 2017 Dec;49(12):1752-1757
pubmed: 29083406
Clin Exp Allergy. 2013 Jan;43(1):73-84
pubmed: 23278882
Environ Health Perspect. 2009 Nov;117(11):1791-8
pubmed: 20049134
J Allergy Clin Immunol. 2008 Jan;121(1):141-147.e4
pubmed: 17980410
Eur Respir J. 2008 Nov;32(5):1250-61
pubmed: 18579540